AccuraGen is at the forefront of cancer diagnostics, focusing on innovative technologies that enhance the accuracy and efficiency of cancer detection and monitoring. Their proprietary approach utilizes liquid biopsy, a non-invasive alternative to traditional tissue biopsies, allowing for the collection of vital genetic information from a patient's blood. This method not only reduces patient discomfort but also enables comprehensive monitoring of disease status over time. AccuraGen's flagship product, the AccuScan assay, employs whole-genome sequencing (WGS) to detect minimal residual disease (MRD) with remarkable sensitivity and specificity. The technology incorporates advanced techniques such as intramolecular ligation and rolling-circle amplification, which facilitate the accurate analysis of circulating tumor DNA (ctDNA) even from samples with low DNA input.

The company's commitment to precision oncology is further demonstrated through its multidisciplinary approach, combining expertise from various fields including mathematics, statistics, and genomics. This collaborative effort aims to convert subtle cancer signals in the blood into actionable diagnostic information. AccuraGen's AccuScan assay has shown promising results in clinical studies, achieving 90% sensitivity and 100% specificity in detecting MRD in colorectal cancer patients. With plans for a clinical rollout in 2026, AccuraGen is poised to significantly impact cancer management by providing clinicians with reliable tools for early detection and monitoring of cancer recurrence, ultimately transforming patient care in the era of personalized medicine.

United States

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

AccuraGen

Company Details